NEW YORK (360Dx) — The US Food and Drug Administration on Friday granted 510(k) clearance to an influenza A and B immunoassay from Quidel.

The test runs on the firm's next-generation immunoassay platform, Sofia 2, which was cleared last month with an assay for respiratory syncytial virus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.